tradingkey.logo
tradingkey.logo
Pesquisar

Avalyn Pharma Ord Shs (Proposed)

AVLN
Adicionar à lista de desejos
30.280USD
-0.310-1.01%
Fechamento 11-13 16:00(ET)
1.34BValor de mercado
0.00P/L TTM

Sobre o Avalyn Pharma Ord Shs (Proposed) Empresa

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase Ib clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.

Avalyn Pharma Ord Shs (Proposed) Perfil

Código da empresa- -
Nome da Empresa- -
Data de listagem- -
CEO- -
Número de funcionários- -
Tipo de títulos- -
Fim do ano fiscal- -
Endereço- -
Cidade- -
Bolsa de valores- -
País- -
Código postal- -
Telefone- -
Site- -
Código da empresa- -
Data de listagem- -
CEO- -

Executivos da empresa Avalyn Pharma Ord Shs (Proposed)

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ketan Patel, M.D.
Dr. Ketan Patel, M.D.
Independent Director
Independent Director
--
--
Ms. Lyn Baranowski
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Dr. Melissa Rhodes, Ph.D.
Dr. Melissa Rhodes, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Howard M. Lazarus, M.D.
Mr. Howard M. Lazarus, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill Carroll
Ms. Jill Carroll
Independent Director
Independent Director
--
--
Mr. Jon Congleton
Mr. Jon Congleton
Independent Director
Independent Director
--
--
Dr. David Friedman, M.D.
Dr. David Friedman, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ketan Patel, M.D.
Dr. Ketan Patel, M.D.
Independent Director
Independent Director
--
--
Ms. Lyn Baranowski
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Dr. Melissa Rhodes, Ph.D.
Dr. Melissa Rhodes, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Howard M. Lazarus, M.D.
Mr. Howard M. Lazarus, M.D.
Chief Medical Officer
Chief Medical Officer
--
--

Perguntas frequentes

Quem são os cinco principais acionistas de Avalyn Pharma Ord Shs (Proposed)?

Os cinco principais acionistas de Avalyn Pharma Ord Shs (Proposed) são: Dr. Ketan Patel, M.D.
tradingkey.logo
Aviso de risco: Nosso site e aplicativo móvel fornecem apenas informações gerais sobre determinados produtos de investimento. A Finsights não oferece, e o fornecimento de tais informações não deve ser interpretado como se a Finsights estivesse oferecendo, aconselhamento financeiro ou recomendação para qualquer produto de investimento.
Os produtos de investimento estão sujeitos a riscos significativos, incluindo a possível perda do valor investido e podem não ser adequados para todos. O desempenho passado dos produtos de investimento não é indicativo de seu desempenho futuro.
A Finsights pode permitir que anunciantes ou afiliados realizem, ou forneçam anúncios em nosso site, ou aplicativo móvel, ou em qualquer parte deles e pode ser compensada por eles com base em sua interação com os anúncios.
 © Copyright: FINSIGHTS MEDIA PTE. LTD. Todos os direitos reservados.